Toponome imaging system: Multiplex biomarkers in oncology

Trends in Molecular Medicine

Volumn 18, Issue 12, 2012, Pages 723-731

  Evans, Robert G ^a,b   Naidu, Babu ^a,c   Rajpoot, Nasir M ^b,d   Epstein, David ^c   Khan, Michael ^b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d QATAR UNIVERSITY   (Qatar)

Author keywords

Cancer stem cells; Drug discovery; Early cancer diagnosis; Heterogeneity; Microenvironment; Multiplex biomarker; Toponome imaging system (TIS)

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DIPYRONE;

CANCER DIAGNOSIS; CARCINOGENESIS; CELL TYPE; CLINICAL DECISION MAKING; DRUG DESIGN; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; TPONOME IMAGING SYSTEM; TUMOR MICROENVIRONMENT;

HUMANS; MASS SPECTROMETRY; MEDICAL ONCOLOGY; MICROSCOPY, FLUORESCENCE; MULTIPROTEIN COMPLEXES; NEOPLASMS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84870238811     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.10.003     Document Type: Review

References (86)

1. Vucic E.A., et al. Translating cancer 'omics' to improved outcomes. Genome Res. 2012, 22:188-195.
2. Schubert W., et al. Next-generation biomarkers based on 100-parameter functional super-resolution microscopy TIS. N. Biotechnol. 2012, 29:599-610.
3. Tian Q., et al. Systems cancer in medicine: towards realization of predictive, preventive, personalised and participatory (P4) medicine. J. Intern. Med. 2012, 271:111-121.
4. Casado-Vela J., et al. Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics. Clin. Transl. Oncol. 2011, 13:617-628.
5. Box C., et al. Tumour-microenvironmental interactions: paths to progression and targets for treatment. Semin. Cancer Biol. 2010, 20:128-138.
6. Makrilia N., et al. Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest. 2009, 27:1023-1037.
7. Vermeulen L., et al. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 2012, 13:e83-e89.
8. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 2010, 316:1324-1331.
9. Udagawa T., Wood M. Tumor-stromal cell interactions and opportunities for therapeutic intervention. Curr. Opin. Pharmacol. 2010, 10:369-374.
10. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 2011, 17:1359-1370.
11. Bautch V.L. Stem cells and the vasculature. Nat. Med. 2011, 17:1437-1443.
12. Shiao S.L., et al. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011, 25:2559-2572.
13. Dalerba P., et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat. Biotechnol. 2011, 29:1120-1127.
14. Shi Q., et al. Single-cell proteomic chip for profiling intracellular signalling pathways in single tumor cells. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:419-424.
15. Pietras A. Cancer stem cells in tumor heterogeneity. Adv. Cancer Res. 2011, 112:255-281.
16. Dieter S.M., et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011, 9:357-365.
17. Snuderl M., et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011, 20:810-817.
18. Lu R., et al. Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding. Nat. Biotechnol. 2011, 29:928-933.
19. Dedeurwaerder S., et al. Unravelling the epigenomic dimension of breast cancers. Curr. Opin. Oncol. 2011, 23:559-565.
20. Gellert P., et al. Gene array analyzer: alternative usage of gene arrays to study alternative splicing events. Nucleic Acids Res. 2012, 40:2414-2425.
21. Malone J.H., Oliver B. Microarrays, deep sequencing and the true measure of the transcriptome. BMC Biol. 2011, 9:34.
22. Pacholski M.L., Winograd N. Imaging with mass spectrometry. Chem. Rev. 1999, 99:2977-3006.
23. Stoeckli M., et al. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat. Med. 2001, 7:494-496.
24. Johann D.J., et al. Profiling solid tumor heterogeneity by LCM and biological MS of fresh-frozen tissue sections. Methods Mol. Biol. 2011, 755:95-106.
25. Navin H., Hicks J. Future medical applications of single-cell sequencing in cancer. Genome Med. 2011, 3:31.
26. Russness H.G., et al. Insight into the heterogeneity of breast cancer through next-generation sequencing. J. Clin. Invest. 2011, 121:3810-3818.
27. Sanchez-Freire V., et al. Microfluid single-cell real-time PCR for comparative analysis of gene expression patterns. Nat. Protoc. 2012, 7:829-838.
28. Lee A.J., Swanton C. Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics. Biochem. Pharmacol. 2011, 83:1013-1020.
29. Barash E., et al. Multiplexed analysis of proteins in tissue using multispectral fluorescence imaging. IEEE Trans. Med. Imaging 2010, 29:1457-2146.
30. Kumarasinghe A.P., et al. DNA mismatch repair enzyme immunohistochemistry in colorectal cancer: a comparison of biopsy and resection material. Pathology 2010, 42:414-420.
31. Hernandez B.Y., et al. CK20 and CK7 protein expression in colorectal cancer: demonstration of the utility of a population-based tissue microarray. Hum. Pathol. 2005, 36:275-281.
32. Chang M.C., et al. 'Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridisation: a study of 2522 cases. Mod. Pathol. 2012, 25:683-688.
33. Kraus J.A., et al. Semi-quantitative immunohistochemical assay versus oncotype DX (®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Mod. Pathol. 2012, 25:869-876.
34. Croswell J.M., et al. Screening for prostate cancer with PSA testing: current status and future directions. Oncology (Williston Park) 2011, 25:452-460.
35. Bihl M.P., et al. KRAS mutation testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13. Diagn. Mol. Pathol. 2012, 21:14-23.
36. Walter A., et al. Genetic, prognostic and predictive markers in colorectal cancer. Nat. Rev. Cancer 2009, 9:489-499.
37. Murphy R.F. Putting proteins on a map. Nat. Biotechnol. 2006, 24:1223-1224.
38. Perfetto S.P., et al. Seventeen-colour flow cytometry: unravelling the immune system. Nat. Rev. Immunol. 2004, 4:648-655.
39. Mondal P.P., Diaspro A. Simultaneous multilayer scanning and detection for multiphoton fluorescence microscopy. Sci. Rep. 2011, 1:149.
40. Balluff B., et al. MALDI imaging mass spectrometry for direct tissue analysis: technological advancements and recent applications. Histochem. Cell Biol. 2011, 136:227-244.
41. Boggio K.J., et al. Recent advances in single-cell MALDI mass spectrometry imaging and potential clinical impact. Expert Rev. Proteomics 2011, 8:591-604.
42. Schubert W. Topological proteomics, toponomics, MELK-technology. Adv. Biochem. Eng. Biotechnol. 2003, 83:189-209.
43. Trede D., et al. Exploring three-dimensional matrix-assisted laser desorption/ionization imaging mass spectrometry data: three-dimensional spatial segmentation of mouse kidney. Anal. Chem. 2012, 84:6079-6087.
44. Schubert W., et al. Analysing proteome topology and function by automated multidimensional fluorescence microscopy. Nat. Biotechnol. 2006, 24:1270-1278.
45. Friedenberg M., et al. Fluorescence detection of protein clusters in individual cells and tissue sections by using toponome imaging system: sample preparation and measuring procedures. Nat. Protoc. 2007, 2:2285-2294.
46. Raza S-e-A., et al. RAMTaB: Robust alignment of multi-tag bioimages. PLoS ONE 2011, 7:e30894.
47. Bhattacharya S., et al. Toponome imaging system: in situ protein network mapping in normal and cancerous colon from the same patient reveals more than five-thousand cancer specific protein clusters and their subcellular annotation by using a three symbol code. J. Proteome Res. 2010, 9:6112-6125.
48. Schubert W., et al. Toponome mapping in prostate cancer: detection of 2000 cell surface protein clusters in a single tissue section and cell type specific annotation by using a three symbol code. J. Proteome Res. 2009, 8:2696-2707.
49. Schubert W. A three-symbol code for organized proteomes based on cyclical imaging of protein locations. Cytometry A 2007, 71:352-360.
50. Van Wyk J.J., Bruton E.T. Molecular basis for species and ligand specificity of a monoclonal antibody raised against human IGF-1. Endocrinology 1997, 138:4521-4522.
51. Essaqhir A., Demoulin J.B. A minimal connected network of transcription factors regulated in human tumors and its application to the quest for universal cancer biomarkers. PLoS ONE 2012, 7:e39666.
52. Berndt U., et al. Comparative Multi-Epitope-Ligand-Cartography reveals essential immunological alterations in Barrett's metaplasia and esophageal adenocarcinoma. Mol. Cancer 2010, 9:177.
53. Bonnekoh B., et al. Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment. Skin Pharmacol. Physiol. 2007, 20:237-252.
54. Dress A.W.M., et al. Poisson numbers and poisson distributions in subset surprisology. Ann. Comb. 2004, 8:473-485.
55. Kolling J., et al. WHIDE - a web tool for visual data mining colocation patterns in multivariate bioimages. Bioinformatics 2012, 28:1143-1150.
56. Humayun A., et al. A novel framework for molecular co-expression pattern analysis in multi-channel toponome fluorescence images. MIAAB 2011 (Proceedings of the 2011 Microscopic Image Analysis with Applications in Biology) 2011, 109-112. MIAAB.
57. Dress A.W.M., et al. Two theorems about similarity maps. Ann. Comb. 2008, 12:279-290.
58. Loyek C., et al. BioIMAX: a web 2.0 approach for easy exploratory and collaborative access to multivariate bioimage data. BMC Bioinform. 2011, 12:297.
59. Herold J., et al. Multivariate image mining. Wiley Interdiscip. Rev. 2011, 1:2-13.
60. Cottingham K. Human Toponome Project. J. Proteome Res. 2008, 7:1806.
61. Sage L. The molecular face of prostate cancer. J. Proteome Res. 2009, 8:2616.
62. Tsai C.J., et al. Protein-protein interaction networks: how can a hub protein bind so many different partners?. Trends Biochem. Sci. 2009, 34:594-600.
63. Cooper T.F., et al. Effect of random and hub gene disruptions on environmental and mutational robustness in Escherichia coli. BMC Genomics 2006, 7:237.
64. Fu Q., et al. Multiplex assays for biomarker research and clinical application: translational science coming of age. Proteomics Clin. Appl. 2010, 4:271-284.
65. Ahlquist D.A., et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012, 142:248-256.
66. Gerges N., Jabado N. Biomarkers in cancer micrometastasis: where are we at?. Bioanalysis 2010, 2:881-899.
67. Potts M.B., Cameron S. Cell lineage and cell death: Caenorhabditis elegans and cancer research. Nat. Rev. Cancer 2011, 11:50-58.
68. Ricci-Vitiani L., et al. Colon cancer stem cells. Gut 2008, 57:538-548.
69. Adams J.M., Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones?. Cancer Res. 2008, 68:4018-4021.
70. Adams J.M., et al. Role of "cancer stem cells" and cell survival in tumor development and maintenance. Cold Spring Harb. Symp. Quant. Biol. 2008, 73:451-459.
71. Community Corner (2008). Capturing cancer stem cells. Nat. Med. 14 PMID: 18685595 814.
72. Boman B.M., Huang E. Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J. Clin. Oncol. 2008, 24:2828-2838.
73. Johnston M.D., et al. On the proportion of cancer stem cells in a tumour. J. Theor. Biol. 2010, 266:708-711.
74. Nguyen L.V., et al. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 2012, 12:133-143.
75. Pietras A. Cancer stem cells in tumor heterogeneity. Adv. Cancer Res. 2011, 112:255-281.
76. Johnson K.W., et al. Fluorescence activated cell sorting: a window on the stem cell. Curr. Pharm. Biotechnol. 2007, 8:133-139.
77. Linke B., et al. Toponomics analysis of drug-induced changes in arachidonic acid-dependent signalling pathways during spinal nociceptive processing. J. Proteome Res. 2009, 8:4851-4859.
78. Hanna E., et al. The tumour microenvironment: a novel target for cancer therapy. Oral Dis. 2009, 15:8-17.
79. Carbacas S.M., et al. The cancer stem cell niche-there goes the neighbourhood?. Int. J. Cancer 2011, 129:2315-2327.
80. Roberts H.R., et al. Colon tumour cells increased PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation. Carcinogenesis 2011, 32:1741-1747.
81. Kaidi A., et al. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat. Cell Biol. 2007, 9:210-217.
82. Wojtkowiak J., et al. Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. Cancer Res. 2012, 72:3938-3947.
83. Greenhough A., et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
84. Friedl P., Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011, 147:992-1009.
85. Treasure T., et al. Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial. Thorax 2012, 67:185-187.
86. Utley M., et al. Better out than in? The resection of pulmonary metastases from colorectal tumours. Operations research for health care delivery engineering. Proceedings of 33rd International Annual Conference on Operational Research Applied to Health Services (ORAHS 2007) 2008, 493-500.